Tharimmune Inc. (THAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tharimmune Inc. (THAR) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.64 Million) by net assets ($469.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Tharimmune Inc. for the company's overall valuation and market capitalisation.
Tharimmune Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tharimmune Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tharimmune Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tharimmune Inc. ranked by their cash flow conversion efficiency. Explore Tharimmune Inc. earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adi Sarana Armada Tbk
JK:ASSA
|
0.091x |
|
Long Bon International Co Ltd
TW:2514
|
-0.003x |
|
Cavotec SA
ST:CCC
|
0.011x |
|
Green Landscaping Group AB (publ)
ST:GREEN
|
0.078x |
|
Biosyent Inc.
V:RX
|
0.069x |
|
PRECIA SA EO -50
F:P1E0
|
N/A |
|
Eolus Vind AB (publ)
ST:EOLU-B
|
0.793x |
|
Hyundai Bngste
KO:004560
|
0.025x |
Annual Cash Flow Conversion Efficiency for Tharimmune Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tharimmune Inc. from 2019 to 2025. View Tharimmune Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $397.93 Million | $-16.13 Million | -0.041x | +99.51% |
| 2024-12-31 | $1.31 Million | $-10.90 Million | -8.337x | -942.85% |
| 2023-12-31 | $9.13 Million | $-7.30 Million | -0.799x | +32.42% |
| 2022-12-31 | $5.54 Million | $-6.56 Million | -1.183x | -610.21% |
| 2021-12-31 | $-4.68 Million | $-1.09 Million | 0.232x | -20.07% |
| 2020-12-31 | $-3.72 Million | $-1.08 Million | 0.290x | -33.35% |
| 2019-12-31 | $-1.62 Million | $-706.11K | 0.435x | -- |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more